Does the media refer more to VRTX or AMZN?

In the previous week, Amazon.com had 345 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 362 mentions for Amazon.com and 17 mentions for Vertex Pharmaceuticals. Amazon.com's average media sentiment score of 1.02 beat Vertex Pharmaceuticals' score of 0.93 indicating that Amazon.com is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 9 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Amazon.com 243 Very Positive mention(s) 46 Positive mention(s) 35 Neutral mention(s) 26 Negative mention(s) 11 Very Negative mention(s) Positive

Does the media refer more to VRTX or AXSM?

In the previous week, Vertex Pharmaceuticals had 11 more articles in the media than Axsome Therapeutics. MarketBeat recorded 17 mentions for Vertex Pharmaceuticals and 6 mentions for Axsome Therapeutics. Vertex Pharmaceuticals' average media sentiment score of 0.93 beat Axsome Therapeutics' score of 0.61 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 9 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VRTX or CRSP?

In the previous week, Vertex Pharmaceuticals and Vertex Pharmaceuticals both had 17 articles in the media. Vertex Pharmaceuticals' average media sentiment score of 0.93 beat CRISPR Therapeutics' score of 0.75 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 9 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 6 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VRTX or EDIT?

In the previous week, Vertex Pharmaceuticals had 9 more articles in the media than Editas Medicine. MarketBeat recorded 17 mentions for Vertex Pharmaceuticals and 8 mentions for Editas Medicine. Vertex Pharmaceuticals' average media sentiment score of 0.93 beat Editas Medicine's score of 0.44 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 9 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, GOOG or VRTX?

Alphabet has higher revenue and earnings than Vertex Pharmaceuticals. Alphabet is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alphabet $402.84B 10.24 $132.17B $19.91 16.94 Vertex Pharmaceuticals $12.00B 11.14 $3.95B $17.18 30.66

Does the media prefer GOOG or VRTX?

In the previous week, Alphabet had 105 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 122 mentions for Alphabet and 17 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.93 beat Alphabet's score of 0.46 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alphabet 46 Very Positive mention(s) 14 Positive mention(s) 38 Neutral mention(s) 16 Negative mention(s) 6 Very Negative mention(s) Neutral Vertex Pharmaceuticals 9 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Vertex Pharmaceuticals (VRTX) Competitors

$526.73 -0.94 (-0.18%)

Closing price 04:00 PM Eastern

Extended Trading

$522.69 -4.04 (-0.77%)

As of 05:38 PM Eastern

Compare

VRTX vs. AMZN, AXSM, CRSP, EDIT, and GOOG

Should you buy Vertex Pharmaceuticals stock or one of its competitors? Vertex Pharmaceuticals's main competitors and comparable companies include Amazon.com (AMZN), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), and Alphabet (GOOG). Companies are selected based on similarities in market, industry, and size.

How does Vertex Pharmaceuticals compare to Amazon.com?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Amazon.com (NASDAQ:AMZN) are related large-cap companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

Vertex Pharmaceuticals has a net margin of 35.00% compared to Amazon.com's net margin of 17.44%. Vertex Pharmaceuticals' return on equity of 23.09% beat Amazon.com's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	35.00%	23.09%	16.72%
Amazon.com	17.44%	18.00%	8.97%

In the previous week, Amazon.com had 345 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 362 mentions for Amazon.com and 17 mentions for Vertex Pharmaceuticals. Amazon.com's average media sentiment score of 1.02 beat Vertex Pharmaceuticals' score of 0.93 indicating that Amazon.com is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	9 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Amazon.com	243 Very Positive mention(s)	46 Positive mention(s)	35 Neutral mention(s)	26 Negative mention(s)	11 Very Negative mention(s)	Positive

Vertex Pharmaceuticals presently has a consensus price target of $575.13, indicating a potential upside of 9.19%. Amazon.com has a consensus price target of $321.19, indicating a potential upside of 30.21%. Given Amazon.com's higher probable upside, analysts plainly believe Amazon.com is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.96
Amazon.com	0 Sell rating(s)	3 Hold rating(s)	56 Buy rating(s)	0 Strong Buy rating(s)	2.95

Vertex Pharmaceuticals has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, Amazon.com has a beta of 1.44, indicating that its stock price is 44% more volatile than the broader market.

91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.2% of Amazon.com shares are owned by institutional investors. 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Comparatively, 8.9% of Amazon.com shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Amazon.com has higher revenue and earnings than Vertex Pharmaceuticals. Amazon.com is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.00B	11.14	$3.95B	$17.18	30.66
Amazon.com	$716.92B	3.71	$77.67B	$12.43	19.84

Summary

Vertex Pharmaceuticals beats Amazon.com on 9 of the 17 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to Axsome Therapeutics?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Axsome Therapeutics (NASDAQ:AXSM) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Vertex Pharmaceuticals has a net margin of 35.00% compared to Axsome Therapeutics' net margin of -24.68%. Vertex Pharmaceuticals' return on equity of 23.09% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	35.00%	23.09%	16.72%
Axsome Therapeutics	-24.68%	-265.55%	-28.10%

In the previous week, Vertex Pharmaceuticals had 11 more articles in the media than Axsome Therapeutics. MarketBeat recorded 17 mentions for Vertex Pharmaceuticals and 6 mentions for Axsome Therapeutics. Vertex Pharmaceuticals' average media sentiment score of 0.93 beat Axsome Therapeutics' score of 0.61 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	9 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Vertex Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.00B	11.14	$3.95B	$17.18	30.66
Axsome Therapeutics	$638.50M	15.27	-$183.17M	-$3.75	N/A

Vertex Pharmaceuticals has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the broader market.

91.0% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 0.2% of Vertex Pharmaceuticals shares are held by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Vertex Pharmaceuticals currently has a consensus price target of $575.13, suggesting a potential upside of 9.19%. Axsome Therapeutics has a consensus price target of $271.00, suggesting a potential upside of 45.59%. Given Axsome Therapeutics' higher probable upside, analysts clearly believe Axsome Therapeutics is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.96
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Vertex Pharmaceuticals beats Axsome Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to CRISPR Therapeutics?

Vertex Pharmaceuticals (NASDAQ:VRTX) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Vertex Pharmaceuticals presently has a consensus price target of $575.13, suggesting a potential upside of 9.19%. CRISPR Therapeutics has a consensus price target of $67.94, suggesting a potential upside of 21.32%. Given CRISPR Therapeutics' higher probable upside, analysts clearly believe CRISPR Therapeutics is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.96
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.67

Vertex Pharmaceuticals has a net margin of 35.00% compared to CRISPR Therapeutics' net margin of -3,368.72%. Vertex Pharmaceuticals' return on equity of 23.09% beat CRISPR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	35.00%	23.09%	16.72%
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%

Vertex Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market.

In the previous week, Vertex Pharmaceuticals and Vertex Pharmaceuticals both had 17 articles in the media. Vertex Pharmaceuticals' average media sentiment score of 0.93 beat CRISPR Therapeutics' score of 0.75 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	9 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	6 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Vertex Pharmaceuticals has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.00B	11.14	$3.95B	$17.18	30.66
CRISPR Therapeutics	$3.51M	1,542.63	-$581.60M	-$4.76	N/A

Summary

Vertex Pharmaceuticals beats CRISPR Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to Editas Medicine?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Editas Medicine (NASDAQ:EDIT) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

In the previous week, Vertex Pharmaceuticals had 9 more articles in the media than Editas Medicine. MarketBeat recorded 17 mentions for Vertex Pharmaceuticals and 8 mentions for Editas Medicine. Vertex Pharmaceuticals' average media sentiment score of 0.93 beat Editas Medicine's score of 0.44 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	9 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Comparatively, 3.1% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Vertex Pharmaceuticals has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market.

Vertex Pharmaceuticals presently has a consensus price target of $575.13, suggesting a potential upside of 9.19%. Editas Medicine has a consensus price target of $5.80, suggesting a potential upside of 123.94%. Given Editas Medicine's higher probable upside, analysts plainly believe Editas Medicine is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.96
Editas Medicine	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Vertex Pharmaceuticals has higher revenue and earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.00B	11.14	$3.95B	$17.18	30.66
Editas Medicine	$40.52M	9.82	-$160.06M	-$0.75	N/A

Vertex Pharmaceuticals has a net margin of 35.00% compared to Editas Medicine's net margin of -157.32%. Vertex Pharmaceuticals' return on equity of 23.09% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	35.00%	23.09%	16.72%
Editas Medicine	-157.32%	-196.63%	-38.17%

Summary

Vertex Pharmaceuticals beats Editas Medicine on 14 of the 17 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to Alphabet?

Alphabet (NASDAQ:GOOG) and Vertex Pharmaceuticals (NASDAQ:VRTX) are related large-cap companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

Alphabet has a net margin of 54.77% compared to Vertex Pharmaceuticals' net margin of 35.00%. Alphabet's return on equity of 51.32% beat Vertex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alphabet	54.77%	51.32%	35.42%
Vertex Pharmaceuticals	35.00%	23.09%	16.72%

27.3% of Alphabet shares are held by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are held by institutional investors. 13.0% of Alphabet shares are held by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Alphabet had 105 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 122 mentions for Alphabet and 17 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.93 beat Alphabet's score of 0.46 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alphabet	46 Very Positive mention(s)	14 Positive mention(s)	38 Neutral mention(s)	16 Negative mention(s)	6 Very Negative mention(s)	Neutral
Vertex Pharmaceuticals	9 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Alphabet has higher revenue and earnings than Vertex Pharmaceuticals. Alphabet is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alphabet	$402.84B	10.24	$132.17B	$19.91	16.94
Vertex Pharmaceuticals	$12.00B	11.14	$3.95B	$17.18	30.66

Alphabet currently has a consensus price target of $419.93, suggesting a potential upside of 24.49%. Vertex Pharmaceuticals has a consensus price target of $575.13, suggesting a potential upside of 9.19%. Given Alphabet's stronger consensus rating and higher possible upside, equities analysts clearly believe Alphabet is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alphabet	0 Sell rating(s)	4 Hold rating(s)	34 Buy rating(s)	6 Strong Buy rating(s)	3.05
Vertex Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.96

Alphabet has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market.

Summary

Alphabet beats Vertex Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

Get Vertex Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRTX vs. The Competition

Export

Metric	Vertex Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$133.68B	$3.94B	$7.26B	$13.03B
Dividend Yield	N/A	3.63%	2.52%	14.03%
P/E Ratio	30.66	13.73	274.72	25.67
Price / Sales	11.14	1,309.75	606.70	80.64
Price / Cash	29.94	40.88	28.02	35.00
Price / Book	7.16	15.33	10.49	6.43
Net Income	$3.95B	-$22.71M	$3.50B	$360.21M
7 Day Performance	2.28%	-4.79%	-3.03%	-2.82%
1 Month Performance	-2.76%	-8.35%	-4.16%	-4.06%
1 Year Performance	33.24%	27.10%	13.20%	3.86%

Vertex Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRTX Vertex Pharmaceuticals	3.668 of 5 stars	$526.73 -0.2%	$575.13 +9.2%	+36.8%	$133.68B	$12.00B	30.66	6,400	Analyst Forecast
AMZN Amazon.com	4.9824 of 5 stars	$258.45 +1.9%	$321.19 +24.3%	+12.0%	$2.79T	$775.68B	20.79	1,576,000	Trending News
AXSM Axsome Therapeutics	3.154 of 5 stars	$205.49 -1.1%	$267.60 +30.2%	+66.1%	$10.76B	$638.50M	N/A	925	Analyst Forecast
CRSP CRISPR Therapeutics	2.5326 of 5 stars	$58.33 +3.1%	$67.94 +16.5%	-12.3%	$5.64B	$3.51M	N/A	393	Analyst Forecast
EDIT Editas Medicine	2.2763 of 5 stars	$2.83 +4.8%	$6.00 +112.0%	-22.5%	$434.63M	$40.52M	N/A	87

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRTX) was last updated on 9/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vertex Pharmaceuticals (VRTX) Competitors

VRTX vs. AMZN, AXSM, CRSP, EDIT, and GOOG

How does Vertex Pharmaceuticals compare to Amazon.com?

Summary

How does Vertex Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does Vertex Pharmaceuticals compare to CRISPR Therapeutics?

Summary

How does Vertex Pharmaceuticals compare to Editas Medicine?

Summary

How does Vertex Pharmaceuticals compare to Alphabet?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRTX vs. The Competition

Vertex Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vertex Pharmaceuticals (VRTX) Competitors

VRTX vs. AMZN, AXSM, CRSP, EDIT, and GOOG

How does Vertex Pharmaceuticals compare to Amazon.com?

Is VRTX or AMZN more profitable?

Does the media refer more to VRTX or AMZN?

Do analysts prefer VRTX or AMZN?

Which has more volatility & risk, VRTX or AMZN?

Do institutionals & insiders have more ownership in VRTX or AMZN?

Which has better valuation and earnings, VRTX or AMZN?

Summary

How does Vertex Pharmaceuticals compare to Axsome Therapeutics?

Is VRTX or AXSM more profitable?

Does the media refer more to VRTX or AXSM?

Which has preferable valuation and earnings, VRTX or AXSM?

Which has more volatility and risk, VRTX or AXSM?

Do insiders and institutionals hold more shares of VRTX or AXSM?

Do analysts prefer VRTX or AXSM?

Summary

How does Vertex Pharmaceuticals compare to CRISPR Therapeutics?

Do institutionals and insiders hold more shares of VRTX or CRSP?

Do analysts rate VRTX or CRSP?

Is VRTX or CRSP more profitable?

Which has more volatility and risk, VRTX or CRSP?

Does the media favor VRTX or CRSP?

Which has stronger earnings & valuation, VRTX or CRSP?

Summary

How does Vertex Pharmaceuticals compare to Editas Medicine?

Does the media refer more to VRTX or EDIT?

Do insiders & institutionals hold more shares of VRTX or EDIT?

Which has more volatility & risk, VRTX or EDIT?

Do analysts rate VRTX or EDIT?

Which has higher valuation and earnings, VRTX or EDIT?

Is VRTX or EDIT more profitable?

Summary

How does Vertex Pharmaceuticals compare to Alphabet?

Is GOOG or VRTX more profitable?

Do institutionals & insiders hold more shares of GOOG or VRTX?

Does the media prefer GOOG or VRTX?

Which has better valuation and earnings, GOOG or VRTX?

Do analysts prefer GOOG or VRTX?

Which has more risk and volatility, GOOG or VRTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRTX vs. The Competition

Vertex Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools